{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T02:48:08Z","timestamp":1782874088177,"version":"3.54.5"},"reference-count":18,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.farma.2026.02.008","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T20:55:19Z","timestamp":1773176119000},"page":"T225-T231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["[Translated article] Real-world effectiveness and safety of atezolizumab-carboplatin-etoposide regimen in extensive-stage small-cell lung cancer"],"prefix":"10.1016","volume":"50","author":[{"given":"Mar\u00eda Bel\u00e9n","family":"Aznar de la Riera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Mar\u00eda","family":"Valencia Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adela","family":"Garc\u00eda-Avello Fern\u00e1ndez-Cueto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Victoria","family":"Villaca\u00f1as Palomares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerea","family":"Mu\u00f1oz Unceta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Fern\u00e1ndez Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Barbadillo Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Rioja Carrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Valero Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Mart\u00ednez Callejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.farma.2026.02.008_bb0005","series-title":"Red Espa\u00f1ola de Registros de C\u00e1ncer","article-title":"Las cifras del c\u00e1ncer en Espa\u00f1a 2025","author":"Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica","year":"2025"},{"issue":"8","key":"10.1016\/j.farma.2026.02.008_bb0010","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032899","article-title":"Non-small cell lung cancer (NSCLC): a review of risk factors, diagnosis, and treatment","volume":"102","author":"Alduais","year":"2023","journal-title":"Med (Baltimore)"},{"issue":"9","key":"10.1016\/j.farma.2026.02.008_bb0015","doi-asserted-by":"crossref","first-page":"8129","DOI":"10.3390\/ijms24098129","article-title":"Small-cell lung cancer\u2014an update on targeted and immunotherapies","volume":"24","author":"McNamee","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.farma.2026.02.008_bb0020","series-title":"Informe de posicionamiento terap\u00e9utico de atezolizumab (tecentriq) en combinaci\u00f3n con quimioterapia en c\u00e1ncer de pulm\u00f3n microc\u00edtico en primera l\u00ednea","author":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios","year":"2021"},{"issue":"1","key":"10.1016\/j.farma.2026.02.008_bb0025","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer immunotherapy: progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol Cancer"},{"issue":"9","key":"10.1016\/j.farma.2026.02.008_bb0030","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1007\/s12094-023-03216-3","article-title":"SEOM-GECP clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)","volume":"25","author":"Garc\u00eda-Campelo","year":"2023","journal-title":"Clin Transl Oncol"},{"issue":"7","key":"10.1016\/j.farma.2026.02.008_bb0035","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.farma.2026.02.008_bb0040","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.farma.2026.02.008_bb0045","series-title":"Tecentriq: Resumen de Las caracter\u00edsticas del Producto","author":"European Medicines Agency (EMA)","year":"2020"},{"issue":"3","key":"10.1016\/j.farma.2026.02.008_bb0050","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1177\/10781552241242096","article-title":"A real-world multicentre evaluation of atezolizumab plus platinum-etoposide chemotherapy as first-line treatment in patients with extensive-stage small cell lung cancer in Italy","volume":"31","author":"Musicco","year":"2025","journal-title":"J Oncol Pharm Pract"},{"issue":"12","key":"10.1016\/j.farma.2026.02.008_bb0055","article-title":"A real-world evaluation of atezolizumab plus platinum-etoposide chemotherapy in patients with extensive-stage SCLC in Canada","volume":"2","author":"Elegbede","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.farma.2026.02.008_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107379","article-title":"Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: results of the IFCT-1905 CLINATEZO real-world study","volume":"185","author":"Falchero","year":"2023","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.farma.2026.02.008_bb0065","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.farma.2026.02.008_bb0070","series-title":"Common terminology criteria for adverse events (CTCAE), version 5.0","author":"National Cancer Institute (NCI)","year":"2017"},{"issue":"6","key":"10.1016\/j.farma.2026.02.008_bb0075","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.farma.2026.02.008_bb0080","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00262-021-03052-w","article-title":"Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience","volume":"71","author":"Lee","year":"2022","journal-title":"Cancer Immunol Immunother"},{"issue":"18","key":"10.1016\/j.farma.2026.02.008_bb0085","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.3390\/cancers15184593","article-title":"Evaluation of real-life chemoimmunotherapy combination in patients with metastatic small cell lung carcinoma (SCLC): a multicentric case-control study","volume":"15","author":"Ezzedine","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.farma.2026.02.008_bb0090","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1007\/s00432-022-04087-x","article-title":"Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group","volume":"148","author":"G\u00fcrb\u00fcz","year":"2022","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326000206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326000206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T02:33:11Z","timestamp":1782873191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634326000206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1130634326000206"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2026.02.008","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Real-world effectiveness and safety of atezolizumab-carboplatin-etoposide regimen in extensive-stage small-cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2026.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2025.12.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}